Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT04704947
Recruiting Phase 3

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

NCT04704947 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Started
2017-10-01
Last updated
2021-01-12

Condition(s) studied

Beta Blocker Toxicity

Investigational drug(s) / intervention(s)

nonselective beta blocker →cardio-selective beta blocker groupalendronate sodium →

nonselective beta blocker: nonselective beta blocker

cardio-selective beta blocker group: cardio-selective beta blocker group

alendronate sodium: alendronate sodium

Study summary

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * • Male \& female osteoporotic patient aged ≥ 50 years * Hypertensive \& normotensive patients * BMD T-score ≥ 2.5 or more SD below peak bone mass Exclusion Criteria: * Patients on drugs that may improve osteoporosis disease state such as: * Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins. Patients on drugs that may worsen osteoporosis disease state such as: • Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Tanta Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Citicoline as Neuroprotector in Neonates Exposed to Hypoxia Recruiting
Pantoprazole in Cisplatin Nephrotoxicity Recruiting
Docosahexaenoic Acid on Breath Holding Spells in Children Recruiting
Effect of Some Drugs on Rheumatoid Arithritis Activity Recruiting
Effect of Some Drugs on Liver Fibrosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04704947 on ClinicalTrials.gov ↗ ← All trials in Egypt